Global Cancer Biopsy Market

MARKET SCOPE:

The global Cancer Biopsy market is projected to grow significantly, registering a CAGR of 8.8% during the forecast period (2024 – 2032).

A cancer biopsy is a medical procedure in which a sample of tissue or cells is taken from a suspicious area in the body for examination under a microscope. The primary goal of a biopsy is to determine whether the tissue or cells are cancerous (malignant) or non-cancerous (benign). Biopsies are essential for diagnosing cancer, determining its type, grade, and stage, and guiding treatment decisions. This involves using a thin needle to extract a sample of tissue or cells from the suspicious area. Needle biopsies can be performed using various techniques, such as fine-needle aspiration (FNA), core needle biopsy, or vacuum-assisted biopsy. In some cases, a surgical procedure may be necessary to obtain a biopsy sample. This may involve removing part or all of the suspicious tissue, either through open surgery or minimally invasive techniques. Increasing awareness about the importance of early cancer detection and the role of biopsies in diagnosing cancer has led to more patients seeking medical evaluation and biopsy procedures when necessary. The development of new cancer therapies and diagnostic technologies often requires biopsy samples for research purposes and clinical trials, contributing to the demand for biopsy procedures.

MARKET OVERVIEW:

Driver: Increasing demand for minimally invasive techniques is driving the market growth

The development and adoption of minimally invasive biopsy techniques represent a significant advancement in the field of cancer diagnostics. These techniques, including fine-needle aspiration (FNA) and core needle biopsy, offer several benefits that enhance the overall patient experience and improve the accessibility of biopsy procedures. Minimally invasive biopsy techniques are generally associated with less discomfort and pain compared to traditional open surgical biopsies. Patients often experience fewer post-procedural complications, contributing to overall comfort and satisfaction. Minimally invasive biopsies typically result in shorter recovery times compared to more invasive procedures. Patients may experience less postoperative pain and a quicker return to normal activities, allowing for a faster overall recovery process. Many minimally invasive biopsy techniques can be performed on an outpatient basis, eliminating the need for hospitalization. This not only reduces healthcare costs but also allows patients to undergo the procedure and return home on the same day. Minimally invasive techniques often involve smaller incisions or no incisions at all, leading to a lower risk of infection, bleeding, and other complications. This makes these procedures safer for a broader range of patients, including those with underlying health conditions. The less invasive nature of these biopsy techniques makes them more accessible to a broader patient population. Individuals who may be hesitant to undergo traditional open surgical procedures may be more willing to consider minimally invasive biopsies, thus improving overall biopsy rates.

Opportunities: Advancements in diagnostic techniques is anticipated for the market growth in the upcoming years.

Advancements in diagnostic technologies have indeed played a pivotal role in revolutionizing cancer biopsy procedures, leading to more precise diagnoses and personalized treatment plans. Improved imaging technologies, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT), allow for more detailed visualization of tumors and surrounding tissues. High-resolution imaging aids in guiding biopsy procedures, ensuring accurate tissue sampling and reducing the need for more invasive methods. Molecular profiling involves analyzing the genetic and molecular characteristics of tumors. This information helps in identifying specific mutations and alterations that drive cancer growth. Biopsies guided by molecular profiling provide valuable insights into the unique genetic makeup of individual tumors, facilitating targeted and personalized treatment strategies. Liquid biopsy is a non-invasive technique that involves analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or other biomarkers in blood or other bodily fluids. This approach enables the detection of cancer-related genetic alterations without the need for a traditional tissue biopsy. Liquid biopsy is particularly valuable for monitoring treatment response and detecting minimal residual disease.

COVID IMPACT:

During the peak periods of the pandemic, many healthcare facilities were overwhelmed with COVID-19 cases, leading to disruptions in routine healthcare services, including cancer screenings and diagnostic procedures. Non-urgent medical procedures, including certain cancer biopsies, were delayed or canceled to prioritize resources for COVID-19 patients. Fear of infection and lockdowns led to a decrease in routine medical visits, including those related to cancer screenings. Patients may have postponed or avoided seeking medical attention, potentially resulting in delayed cancer diagnoses and biopsy procedures. Population-based cancer screening programs, such as mammography for breast cancer or colonoscopy for colorectal cancer, experienced disruptions. This could affect the timely detection of cancer cases that would typically lead to biopsy procedures. The global supply chain disruptions caused by the pandemic may have affected the availability of biopsy-related consumables and equipment. This could lead to challenges in maintaining a steady supply of necessary materials for biopsy procedures. The pandemic accelerated the adoption of telemedicine and virtual consultations. While this facilitated remote patient-doctor interactions, certain aspects of cancer diagnosis, such as physical examinations and tissue sampling through biopsy, require in-person visits, potentially causing delays. Research efforts and resources were redirected towards understanding and combating COVID-19. This temporary shift in focus may have impacted ongoing cancer research and the development of new biopsy technologies.

SEGMENTATION ANALYSIS:

Breast Cancer segment is anticipated to grow significantly during the forecast period

Breast cancer is one of the most common cancers globally. As the incidence of breast cancer continues to rise, the demand for diagnostic tools, including biopsy procedures, is likely to increase. Early detection is crucial for successful treatment outcomes in breast cancer. Biopsy plays a key role in confirming the presence of cancer, determining its characteristics, and guiding treatment decisions. Efforts to promote early detection and screening may drive growth in breast cancer biopsy procedures. Improved imaging technologies, such as mammography, ultrasound, and magnetic resonance imaging (MRI), may contribute to more accurate and targeted biopsy procedures for breast cancer. Integration of these technologies with biopsy techniques can enhance diagnostic capabilities.

The Kits and Consumables segment is anticipated to grow significantly during the forecast period

The anticipation of significant growth in the Kits and Consumables segment within the context of cancer biopsy suggests that there is an expected increase in demand for biopsy-related products and consumables over the forecast period. With the rising incidence of cancer, there is a growing need for diagnostic tools, including biopsy kits and consumables. As more people undergo cancer screening and diagnostic procedures, the demand for related products is likely to increase. Advances in biopsy technologies often come with the development of new and improved kits and consumables. These may include specialized reagents, sample collection devices, and other consumables necessary for conducting efficient and accurate biopsy procedures. The trend towards personalized medicine, where treatments are tailored based on individual patient characteristics, has increased the demand for specific kits and consumables that support molecular profiling and genetic testing during the biopsy process.

REGIONAL ANALYSIS:

The North American region is set to witness significant growth during the forecast period.

Continuous developments in diagnostic technologies and techniques for cancer biopsy have indeed been a significant factor in improving the accuracy and efficiency of cancer detection in the United States. The development of more advanced imaging technologies, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT), has enhanced the precision of cancer detection and localization. Liquid biopsy is an emerging and promising technique that involves analyzing components like circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood. This non-invasive method can provide valuable information about the presence and characteristics of tumors. Advances in molecular diagnostics and the understanding of genetic markers associated with specific cancers have paved the way for personalized and targeted therapies. Biopsy techniques that involve molecular profiling help tailor treatment plans based on an individual's genetic makeup. The development of minimally invasive biopsy techniques, such as fine-needle aspiration (FNA) or core needle biopsy, allows for more efficient and less invasive tissue sampling, reducing patient discomfort and recovery time. AI and machine learning applications are being increasingly incorporated into diagnostic processes. These technologies can analyze complex data sets, assist in image interpretation, and improve the overall accuracy of cancer detection.

COMPETITIVE ANALYSIS

The global Cancer Biopsy market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.

Qiagen NV

• The forensic science NGS company Verogen was acquired by Qiagen in January 2024, a move that would expand the company's product line and boost its standing internationally Illumina Inc.

BillioToOne

• BillionToOne released the liquid biopsy product in July 2023; this product delivers an accurate measurement of the tumor burden without requiring the tumor tissue.

ANGLE Plc

BD (Becton, Dickinson and Company)

Myriad Genetics

Hologic, Inc.

Biocept, Inc.

Thermo Fisher Scientific, Inc.

Danaher

F. Hoffmann-La Roche Ltd.

Lucence Diagnostics Pte. Ltd.

GRAIL, Inc.

Guardant Health

Exact Sciences Corporation

SCOPE OF THE REPORT

By Application

• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Lung Cancer
• Prostate Cancer
• Ovarian Cancers
• Other Applications

By Product Type

• Instruments
• Kits and Consumables
• Services

By Region

• North America (the United States & Canada)
• Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
• Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
• Rest of the World (the Middle East & Africa, and Latin America)

KEYS REASONS TO PURCHASING THIS REPORT

It provides a technological development map over time to understand the industry’s growth rate and indicates how the Cancer Biopsy market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Cancer Biopsy submarket will be the main driver of the overall market from 2024 to 2032.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032. Show more